slides · global inventory
Source Note
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,355
Current window 46,261-46,290
Pages 3,679
Rows per page 30
Component
46,261-46,290 of 110,355
101
The slide uses Q&A format to highlight potential industry knowledge of safety risks that were not publicly disclosed.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
102
Uses Q&A format to frame expert opinion as a critique of Bioprojet's claims.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
103
The slide presents two distinct expert critiques regarding IP expiration and clinical trial quality, attributed to a senior scientist at Johnson & Johnson.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
105
The slide uses a 'quote-and-critique' structure to expose potential data manipulation in clinical reporting.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
106
The slide uses a red box to highlight the 'n=17' discrepancy in the source text.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
107
The slide uses an FDA review document to highlight a safety risk (QTc prolongation) that the company allegedly downplays.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
108
The slide uses a direct quote from a study to argue that 'malaise sensation' is a euphemism for 'fainting' (syncope) to downplay cardiotoxicity.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
110
The slide uses a 'before-after' or 'comparison' structure to highlight the exclusion criteria in two different trial papers.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
111
The slide uses a 'villain critique' style to highlight a lack of transparency in clinical trial reporting.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
112
The slide uses a 'fraud-exposure' narrative to highlight missing safety data in regulatory filings.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
113
The slide uses a critical tone to challenge the integrity of the reported clinical trial data.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
114
The slide uses a critical tone to highlight potential data manipulation or poor reporting practices in a clinical trial publication.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
115
The slide uses a red underline to emphasize the specific clinical findings in the excerpt.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
116
The slide critiques the authors' interpretation of ECG/QTc data in the HAROSA 2 trial, pointing out potential bias or omission.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
118
The slide uses a 'black box' argument to challenge the validity of the sponsor's pharmacokinetic model.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
119
The slide uses direct quotes from the EMA's CHMP assessment report to highlight regulatory discrepancies.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
120
The slide uses a combination of narrative argument and a direct quote from a consultant to build a case against the company's transparency.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
121
The slide presents a direct quote from a PK expert to undermine the validity of the company's safety assertions.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
122
The slide uses a 'before-after' or 'comparison' logic to expose data manipulation in clinical reporting.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
123
The slide uses a red box to highlight a specific data point (40mg dose) in a table to support the argument of inconsistent reporting.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
124
The slide uses a specific FDA review document (NDA 211150) to challenge official plasma level claims.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
125
The slide uses a specific data table to support a broader narrative of corporate non-transparency regarding PK data.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
128
The slide uses a direct quote from an FDA clinical review to contradict the company's safety claims, supported by a table of clinical data.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
130
The slide uses direct citations from FDA and research documents to highlight the discrepancy between single-dose study designs and the need for steady-state peak plasma concentration analysis.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
132
The slide highlights a specific discrepancy in an FDA review document (page 32) where the graph title claims 'steady state Cmax' but the underlying data is from a single dose.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
134
The slide documents the source data used by a consultant to derive a linear regression model for QTc vs. plasma levels.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
135
The slide uses a 'before-after' logic to expose a flaw in regulatory reliance on single-dose data. The red box highlights the critical 'Upper limit TQT' values in the corrected table.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
136
Includes a linear regression equation Y=14.62*X+53.34 and a scatter plot with error bars.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
138
The slide uses direct excerpts from the drug's prescribing information to build a case against its safety profile.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
139
The slide uses a direct excerpt from a package insert to support the argument that dose reduction is required due to drug interactions.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit